Publications

Results 1-22 of 22 (Search time: 0.006 seconds).

Issue DateTitleAuthor(s)SourcescopusWOSFulltext/Archive link
12021Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLCBIN-CHI LIAO ; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H.JTO Clinical and Research Reports0
22021Lung Cancer in Republic of ChinaLuo Y.-H.; Chiu C.-H.; Scott Kuo C.-H.; Chou T.-Y.; Yeh Y.-C.; Hsu H.-S.; Yen S.-H.; Wu Y.-H.; Yang J.C.-H.; BIN-CHI LIAO ; Hsia T.-C.; Chen Y.-M.Journal of Thoracic Oncology3
32021CD73 Is regulated by the EGFR-ERK signaling pathway in non-small cell lung cancerGriesing S.; BIN-CHI LIAO ; Yang J.C.-H.Anticancer Research4
42020Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitorsYang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; BIN-CHI LIAO ; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.European Journal of Cancer23
52020Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving CrizotinibYang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; BIN-CHI LIAO ; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.Oncologist8
62020Exon 16�VSkipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M�VPositive Non�VSmall Cell Lung CancerHsu C.-C.; BIN-CHI LIAO ; Liao W.-Y.; Markovets A.; Stetson D.; Thress K.; Yang J.C.-H.Journal of Thoracic Oncology22
72019Second-line treatment of EGFR T790M-negative non-small cell lung cancer patientsBIN-CHI LIAO ; Griesing S.; Yang J.C.-H.Therapeutic Advances in Medical Oncology7
82018Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in TaiwanLin S.-Y.; Yang C.-Y.; BIN-CHI LIAO ; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J.Journal of Cancer31
92018Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitorsBIN-CHI LIAO ; Bai Y.-Y.; Lee J.-H.; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Chih-Hsin Yang J.; Yang P.-C.Journal of the Formosan Medical Association7
102018Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?BIN-CHI LIAO ; Lin C.-C.; Yang J.C.-H.Expert Opinion on Pharmacotherapy4
112017Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosisGuo J.-C.; Chang C.-C.; Yang C.-Y.; BIN-CHI LIAO ; Liau J.-Y.; Chang C.-H.; Yeh K.-H.Medical Oncology1
122017Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapyBIN-CHI LIAO ; Lin C.-C.; Lee J.-H.; Yang J.C.-H.Lung Cancer29
132017Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of AfatinibBIN-CHI LIAO ; Lin C.-C.; Yang J.C.-H.Current Oncology Reports17
142016151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIsBIN-CHI LIAO ; Bai Y.-Y.; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Yang J.Journal of Thoracic Oncology1
152016Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practiceLiang Y.-H.; Shao Y.-Y.; BIN-CHI LIAO ; Lee H.-S.; Yang J.C.-H.; Chen H.-M.; Chiang C.-J.; Cheng A.-L.; Lai M.-S.Journal of Cancer6
162016Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitorsBIN-CHI LIAO ; Lin C.-C.; Lee J.-H.; Yang J.C.-H.Journal of Biomedical Science31
172015Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinomaBIN-CHI LIAO ; Shao Y.-Y.; Chen H.-M.; Shau W.-Y.; Lin Z.-Z.; Kuo R.N.; Lai C.-L.; Chen K.-H.; Cheng A.-L.; Yang J.C.-H.; Lai M.-S.Clinical Lung Cancer8
182015Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal CarcinomatosisBIN-CHI LIAO ; Lee J.-H.; Lin C.-C.; Chen Y.-F.; Chang C.-H.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H.Journal of Thoracic Oncology81
192015Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancerBIN-CHI LIAO ; Lin C.-C.; Yang J.C.-H.Current Opinion in Oncology92
202015Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategyBIN-CHI LIAO ; Lin C.C.; Shih J.Y.; Yang J.C.H.Therapeutic Advances in Medical Oncology16
212013First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developmentsBIN-CHI LIAO ; Lin C.-C.; Yang J.C.-H.Drugs16
222012Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH studyBIN-CHI LIAO ; Yang J.C.-H.Translational Lung Cancer Research0